The EMPEROR-Reduced and DAPA-HF trials illustrate the effectiveness of SGLT2 inhibitors in HFrEF treatment, highlighting substantial reductions in the risk of hospitalization and cardiovascular death [31,32]. The gene discussed is SLC5A2; the disease is hydrops fetalis.